BG105128A - Терапевтични комбинации на (селективни) модулатори на рецептора на естроген (serm) и растежен фактор секретагог (ghs) за лечение на мускулноскелетна слабост - Google Patents

Терапевтични комбинации на (селективни) модулатори на рецептора на естроген (serm) и растежен фактор секретагог (ghs) за лечение на мускулноскелетна слабост

Info

Publication number
BG105128A
BG105128A BG105128A BG10512801A BG105128A BG 105128 A BG105128 A BG 105128A BG 105128 A BG105128 A BG 105128A BG 10512801 A BG10512801 A BG 10512801A BG 105128 A BG105128 A BG 105128A
Authority
BG
Bulgaria
Prior art keywords
ghs
serm
growth hormone
compositions
estrogen receptor
Prior art date
Application number
BG105128A
Other languages
English (en)
Inventor
Hua KE
Mei Li
Lydia PAN
David Thompson
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG105128A publication Critical patent/BG105128A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретението се отнася до фармацевтични състави и до методи, които се използват за лечение на мускулно-скелетна слабост, включително остеопороза, остеопорозни фрактури, малка костна маса и малка мускулна маса. Съставите съдържат (-)-цис-6-фенил-5- (4-(2-пиролидин-1-ил- етокси)-фенил)- 5,6,7,8- тетрахидро-нафтален-2- ол или негова фармацевтично приемлива сол и 2-амино-N-(1-(R)- 2,4-дифлуоро-бензилоксиметил)-2- оксо-2-(3-оксо-3а(R)- пиридин-2-илметил)-2- (2,2,2-трифлуоро-етил)- 2,3,3а,4,6,7-хексахидро-пиразоло[4,3-с] пиридин-5-ил)-етил)- 2-метил- пропионамид или негова фармацевтично приемлива сол.
BG105128A 1998-06-16 2001-01-08 Терапевтични комбинации на (селективни) модулатори на рецептора на естроген (serm) и растежен фактор секретагог (ghs) за лечение на мускулноскелетна слабост BG105128A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16
PCT/IB1999/000796 WO1999065488A1 (en) 1998-06-16 1999-05-03 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Publications (1)

Publication Number Publication Date
BG105128A true BG105128A (bg) 2001-11-30

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105128A BG105128A (bg) 1998-06-16 2001-01-08 Терапевтични комбинации на (селективни) модулатори на рецептора на естроген (serm) и растежен фактор секретагог (ghs) за лечение на мускулноскелетна слабост

Country Status (29)

Country Link
EP (1) EP1085867A1 (bg)
JP (1) JP2002518328A (bg)
KR (1) KR20010052817A (bg)
CN (1) CN1305378A (bg)
AP (1) AP9901581A0 (bg)
AR (1) AR018868A1 (bg)
AU (1) AU3342099A (bg)
BG (1) BG105128A (bg)
BR (1) BR9911357A (bg)
CA (1) CA2335112A1 (bg)
CO (1) CO5070586A1 (bg)
EA (1) EA200001189A1 (bg)
GT (1) GT199900083A (bg)
HR (1) HRP20000857A2 (bg)
HU (1) HUP0102395A2 (bg)
ID (1) ID26726A (bg)
IL (1) IL139587A0 (bg)
IS (1) IS5727A (bg)
MA (1) MA26648A1 (bg)
NO (1) NO20006381D0 (bg)
OA (1) OA11569A (bg)
PA (1) PA8472101A1 (bg)
PE (1) PE20000633A1 (bg)
PL (1) PL345064A1 (bg)
SK (1) SK18902000A3 (bg)
TN (1) TNSN99118A1 (bg)
UY (1) UY25557A1 (bg)
WO (1) WO1999065488A1 (bg)
ZA (1) ZA993973B (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
ES2319785T3 (es) * 2001-11-29 2009-05-12 Gtx, Inc. Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
UY25557A1 (es) 2001-01-31
PA8472101A1 (es) 2000-09-29
ID26726A (id) 2001-02-01
EP1085867A1 (en) 2001-03-28
IS5727A (is) 2000-11-24
WO1999065488A1 (en) 1999-12-23
PL345064A1 (en) 2001-11-19
TNSN99118A1 (fr) 2005-11-10
EA200001189A1 (ru) 2001-06-25
JP2002518328A (ja) 2002-06-25
PE20000633A1 (es) 2000-07-26
BR9911357A (pt) 2001-03-13
HUP0102395A2 (hu) 2001-11-28
KR20010052817A (ko) 2001-06-25
AP9901581A0 (en) 1999-06-30
IL139587A0 (en) 2002-02-10
HRP20000857A2 (en) 2001-10-31
NO20006381L (no) 2000-12-14
OA11569A (en) 2004-07-01
CN1305378A (zh) 2001-07-25
MA26648A1 (fr) 2004-12-20
CA2335112A1 (en) 1999-12-23
AU3342099A (en) 2000-01-05
AR018868A1 (es) 2001-12-12
NO20006381D0 (no) 2000-12-14
ZA993973B (en) 2000-12-15
SK18902000A3 (sk) 2001-12-03
CO5070586A1 (es) 2001-08-28
GT199900083A (es) 2000-12-05

Similar Documents

Publication Publication Date Title
JO1613B1 (en) Derivatives of n - (3-hydroxy-4-piperidnil) dihydrobenzofuran, dihydro-2u-benzopyran or dihydro-benzodoxine) carboxymide
EE04018B1 (et) Tieno[2,3-d]pürimidiindioonid, nende valmistamisemeetod ja neid sisaldavad ravimkoostised
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
DE69827977D1 (de) Spiro [1-azabicyclo[2.2.2]octan-3,2'(3'H)-furo[2,3-b]pyridin zur Verwendung in der Behandlung von psychotischen und intellektuellen Störungen
MY132642A (en) Naphthyridine derivatives
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
BG105128A (bg) Терапевтични комбинации на (селективни) модулатори на рецептора на естроген (serm) и растежен фактор секретагог (ghs) за лечение на мускулноскелетна слабост
AU1945795A (en) Thieno{ 2,3-b}indoles, their preparation and use
PL334228A1 (en) Derivatives of pyrrolo[3,4-d]pyrimidinone and their application as drugs
DE69738185D1 (de) Verfahren zur Herstellung eines bluddrucksenkenden Mittel enthaltenden ein Dipeptid als wirksames Bestandteil
BG105041A (bg) ЛЕЧЕБНИ КОМБИНАЦИИ ОТ (СЕЛЕКТИВНИ) ЕСТРОГЕННИ РЕЦЕПТОРНИ МОДУЛАТОРИ (SERM) И РАСТЕЖНИ ХОРМОННИ СЕКРЕТАГОГИ (GHs) ЗА ЛЕЧЕНИЕ НА МУСКУЛОСКЕЛЕТНА СЛАБОСТ
EP0335483A3 (en) Condensed imidazole derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them.
BG105125A (bg) Терапевтични комбинации, съдържащи селективен модулатор на естрогенния рецептор и хормон на щитовидната жлеза
WO2001043733A3 (en) Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
EP2140864A3 (en) Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
CA2274381A1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
AU4448497A (en) Novel 6 or 7 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
TH57984A3 (th) การรวมในทางการรักษาซี่งประกอบด้วยตัวปรับตัวรับเอสโตรเจนแบบคัดเลือกและฮอร์โมนพาราไธรอยด์
IL150405A0 (en) BENZOISOTHIAZOLE SUBSTITUTED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN TREATING IL-8, GROα, GROβ, GROY AND NAP-2 MEDIATED DISEASES
WO2004034967A3 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety